Bright Minds Biosciences Launches Phase 2a Trial for Novel Prader-Willi Syndrome Treatment
Key Insights
Bright Minds Biosciences (search) has initiated a Phase 2a NOVA study to evaluate BMB-101, a novel 5-HT2C receptor (search) agonist, for treating hyperphagia (search) and neuropsychiatric symptoms in Prader-Willi syndrome (search) patients.
The company nominated BMB-105 (search) as a dedicated clinical candidate for PWS, with plans to reduce time to market by approximately one year through this dual-compound development strategy.
BMB-101 has demonstrated strong safety profile in Phase 1 studies with 64 healthy volunteers, showing no serious adverse events and robust central target engagement through biomarker studies.
Bright Minds Biosciences (search) Inc. has launched its Prader-Willi Syndrome (search) (PWS) program with the initiation of a Phase 2a clinical trial evaluating BMB-101, a novel 5-HT2C receptor (search) agonist designed to address both hyperphagia (search) and neuropsychiatric symptoms in patients with this rare genetic disorder. The company simultaneously nominated BMB-105 (search) as a new clinical candidate for dedicated PWS development, representing what could be the first on-target mechanism specifically addressing the underlying pathophysiology of PWS.
Novel Mechanism Targets Core PWS Symptoms
The NOVA study represents a proof-of-pharmacology approach designed to demonstrate that 5-HT2C agonism can address the complex symptom profile in PWS patients. According to Ian McDonald, CEO and Co-founder of Bright Minds Biosciences (search), "5-HT2C agonism offers a novel mechanism for PWS by targeting the underlying aspects of the disease. This proof-of-pharmacology clinical study is designed to evaluate BMB-101's utility in addressing both hyperphagia (search) and the behavioral/neuropsychiatric symptoms of PWS."
BMB-101 is engineered as a novel scaffold 5-HT2C Gq-protein (search) biased agonist, developed using structure-based drug design specifically for chronic treatment of neurological disorders where tolerance and drug resistance are common issues. The compound works exclusively via the Gq-protein signaling pathway while avoiding beta-arrestin (search) activation, which is crucial to minimize the risk of receptor desensitization and tolerance development.
Comprehensive Clinical Trial Design
The NOVA clinical study is structured as a double-blind, randomized, Phase 2a trial lasting up to 16 weeks. The study begins with a 4-week screening period during which hyperphagia (search) and PWS-related behavioral testing will establish the presence and degree of PWS symptoms. Following screening, participants will be randomized in a 1:1 ratio to either BMB-101 or placebo.
The trial design includes a weekly ascending Maximum Tolerated Dose (MTD) titration phase of 4 weeks followed by an 8-week maintenance phase, with 5 clinic visits and 4 telephone visits. Following completion of the maintenance phase, participants may elect to continue into an unblinded, open-label phase to receive BMB-101 for up to 9 months.
The primary objective focuses on assessing the effect of BMB-101 on hyperphagia (search)-related behaviors in patients with PWS, with the primary endpoint measuring change from baseline in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores over time. Secondary objectives include evaluating BMB-101's effect on various associated behavioral disorders in PWS and assessing safety and tolerability.
Strong Preclinical and Early Clinical Foundation
BMB-101 has demonstrated a robust safety profile in Phase 1 clinical studies involving 64 healthy volunteers across Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and food-effects studies. The compound was safe and well tolerated at all doses, with no Serious Adverse Events (SAEs) observed and Adverse Events (AEs) that were mild in nature and consistent with on-target effects for serotonergic drugs.
Target engagement studies using both fluid biomarkers (transient prolactin release) and physical biomarkers (Quantitative Electroencephalogram, qEEG) confirmed robust central target engagement. A qEEG signature typical for anti-epileptic drugs was observed, with selective depression of EEG power at frequencies observed during epileptic seizures, along with potentiation of frontal gamma-power that could indicate potential for improved cognition.
Addressing Critical Unmet Medical Need
Prader-Willi syndrome (search) is a rare genetic neurodevelopmental disorder resulting from abnormal gene expression on chromosome 15, affecting approximately one in every 15,000 live births according to the Prader-Willi Syndrome Association USA. The hallmark feature of PWS is hyperphagia (search) – a chronic, life-threatening condition marked by an unrelenting feeling of hunger, obsessive thoughts about food, an overwhelming drive to eat, and a lack of normal satiety.
These symptoms profoundly affect daily life, placing significant emotional and physical burdens on individuals with PWS and their families. Hyperphagia (search) is associated with serious health risks, including acute complications such as stomach rupture, choking, and accidental death related to food-seeking behaviors, as well as long-term comorbidities such as obesity (search), type 2 diabetes (search), and cardiovascular disease (search).
Individuals with PWS also experience significant neurobehavioral challenges, including emotional dysregulation, compulsivity, temper outbursts, and cognitive impairment, which further impact daily functioning and quality of life. Currently, there are no drugs that can adequately address these issues.
Strategic Development Timeline
Following completion of the ongoing Phase 2a proof-of-pharmacology study with BMB-101, Bright Minds plans to select and advance BMB-105 (search) as the dedicated compound for the PWS program. This dual-compound approach is designed to reduce time to market by approximately one year. The company is also conducting a randomized Phase 1 placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and food effect of BMB-105 in healthy volunteers.
The company has scheduled a Key Opinion Leader event for November 6, 2025, featuring world-renowned PWS experts including Dr. Jennifer Miller from the University of Florida, Dr. Theresa V. Strong from the Foundation for Prader Willi Research (search), and Elizabeth Roof from Vanderbilt University. These experts will provide insights into PWS, current treatment limitations, and quality-of-life challenges for patients and families.
Broader Pipeline Progress
BMB-101 is currently being evaluated in a Phase 2a study in patients with Developmental and Epileptic Encephalopathies (search) and Absence Seizures (search). To date, the compound has been well tolerated with no drug-related Serious Adverse Events or safety signals requiring protocol adjustments. Exposure levels and tolerability achieved are consistent with expectations from Phase 1 studies, supporting dose selection for future studies. Top-line data from this epilepsy (search) program will be released in early January 2026, with the company planning Phase 2/3 studies in DEE in 2026.